The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
Issued on behalf of Conexeu Sciences Inc. With Galderma now presenting clinical data on treating medication-driven facial volume loss, the GLP-1 aesthetics category has gone mainstream — and Conexeu Sciences Inc. (Nasdaq: CNXU) is positioning its regenerative CXU™ platform to compete for it. NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) — Biotech Insider — In […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.